雷珠单抗治疗糖尿病视网膜病变 玻璃体出血患者的疗效分析
CSTR:
作者:
作者单位:

作者简介:

张剑,E-mail :2786995509@qq.com

通讯作者:

中图分类号:

基金项目:

黑龙江省卫生厅科研课题(No :S2010-503)


Therapeutic effect of Ranibizumab in diabetic retinopathy patients with vitreous hemorrhage
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨非严重性增生期糖尿病视网膜病变(N-SPDR)玻璃体出血患者给予玻璃体内注射 雷珠单抗的疗效分析。方法 选取2014 年2 月—2015 年10 月于佳木斯大学附属第一医院诊治N-SPDR 玻 璃体出血患者41 例(47 眼)作为研究对象。根据患者是否接受玻璃体内注射雷珠单抗治疗分为观察组22 例(25 眼)和对照组19 例(22 眼)。对患者行常规治疗并随访2 年,比较两组最佳矫正视力、接受玻璃体切除术治 疗例数及行玻璃体切除术患者硅油填充和并发症发生情况。结果 观察组视力改善程度高于对照组(P <0.05); 观察组患者玻璃体切除率低于对照组(P <0.05);观察组行玻璃体切除术患者硅油填充、剥脱粘连、术中出 血及视网膜裂孔发生率低于对照组(P <0.05)。结论 N-SPDR 玻璃体出血患者注射雷珠单抗疗效较好,可 提高患者视力,降低手术治疗率,并可协助降低玻璃体切除术并发症发生率。

    Abstract:

    Objective To investigate the effect of intravitreal injection of Ranibizumab in patients with nonsecerative proliferative diabetic retinopathy (N-SPDR). Methods This study included 41 cases (47 eyes) of N-SPDR patients with vitreous hemorrhage in First Affiliated Hospital of Jiamusi University from February 2014 to October 2015. According to whether the patients received intravitreal injection of Ranibizumab, there were 22 cases (25 eyes) of the observation group (intravitreal injection of Ranibizumab) and 19 cases (22 eyes) of the control group (without intravitreal injection of Ranibizumab). The two groups of patients were given conventional treatment and followed up for 2 years. The best corrected visual acuity, the number of patients who received vitrectomy, and the incidences of silicone oil filling and complications in the patients undergoing vitrectomy were compared between the two groups. Results The improvement of visual acuity in the observation group was significantly better than that in the control group (P < 0.05). The vitrectomy rate of the observation group was lower than that of the control group (P < 0.05). The incidences of silicone oil filling, exfoliation, intraoperative hemorrhage and retinal breaks of the patients undergoing vitrectomy in the observation group were lower than those in the control group (P < 0.05). Conclusions For N-SPDR patients with vitreous hemorrhage, Ranibizumab vitreous injection has significant effect, can improve patients’ vision, reduce the rate of surgical treatment, and can help to reduce the incidences of complications of vitrectomy.

    参考文献
    相似文献
    引证文献
引用本文

齐艳秀,宿星杰,张剑,王玉清.雷珠单抗治疗糖尿病视网膜病变 玻璃体出血患者的疗效分析[J].中国现代医学杂志,2019,(2):50-53

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-07-28
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-01-31
  • 出版日期:
文章二维码